Prime Medicine Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 146

Employees

  • Stock Symbol
  • PRME

Stock Symbol

  • Share Price
  • $3.55
  • (As of Friday Closing)

Prime Medicine General Information

Description

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 21 Erie Street
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 21 Erie Street
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prime Medicine Stock Performance

As of 20-Nov-2026, Prime Medicine’s stock price is $3.55. Its current market cap is $792M with 223M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.55 $3.84 $2.67 - $5.91 $792M 223M 4.63M -$0.97

Prime Medicine Financials Summary

As of 30-Sep-2026, Prime Medicine has a trailing 12-month revenue of $7.06M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 554,106 531,220 248,711 714,017
Revenue 7,061 4,632 2,983 0
EBITDA (172,524) (197,970) (193,276) (196,570)
Net Income (176,353) (201,142) (195,882) (198,133)
Total Assets 213,855 342,733 297,508 193,851
Total Debt 110,421 116,427 40,794 13,633
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Prime Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Prime Medicine‘s full profile, request access.

Request a free trial

Prime Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Prime Medicine‘s full profile, request access.

Request a free trial

Prime Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide
Drug Discovery
Cambridge, MA
146 As of 2025

Cambridge, MA
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prime Medicine Competitors (4)

One of Prime Medicine’s 4 competitors is Beam Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Beam Therapeutics Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Editas Medicine Formerly VC-backed Cambridge, MA
To view Prime Medicine’s complete competitors history, request access »

Prime Medicine Patents

Prime Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026198578-A1 Genome editing compositions and methods for treatment of alpha-1-antitrypsin deficiency Pending 17-Mar-2025
WO-2026090412-A1 Building blocks for gainac-based lipids Pending 23-Oct-2024
WO-2026090423-A1 Universal lnp compositions Pending 23-Oct-2024
WO-2025111430-A1 Chemical modifications in mrna poly(a) tail Inactive 21-Nov-2023
WO-2025111452-A2 Chemical modifications in pegrna and ngrnas Inactive 21-Nov-2023 C12N15/113
To view Prime Medicine’s complete patent history, request access »

Prime Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prime Medicine ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.85 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Prime Medicine’s complete esg history, request access »

Prime Medicine FAQs

  • When was Prime Medicine founded?

    Prime Medicine was founded in 2019.

  • Where is Prime Medicine headquartered?

    Prime Medicine is headquartered in Cambridge, MA.

  • What is the size of Prime Medicine?

    Prime Medicine has 146 total employees.

  • What industry is Prime Medicine in?

    Prime Medicine’s primary industry is Drug Discovery.

  • Is Prime Medicine a private or public company?

    Prime Medicine is a Public company.

  • What is Prime Medicine’s stock symbol?

    The ticker symbol for Prime Medicine is PRME.

  • What is the current stock price of Prime Medicine?

    As of 20-Nov-2026 the stock price of Prime Medicine is $3.55.

  • What is the current market cap of Prime Medicine?

    The current market capitalization of Prime Medicine is $792M.

  • What is Prime Medicine’s current revenue?

    The trailing twelve month revenue for Prime Medicine is $7.06M.

  • Who are Prime Medicine’s competitors?

    Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine are competitors of Prime Medicine.

  • What is Prime Medicine’s annual earnings per share (EPS)?

    Prime Medicine’s EPS for 12 months was -$0.97.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process